Sentences with phrase «of tumor immunity»

In 1997, he became an immunology professor at the Mayo Clinic, Rochester, Minnesota, where he discovered the B7 - H1 (PD - L1) molecule and the role of the B7 - H1 / PD - 1 pathway in the evasion of tumor immunity.

Not exact matches

«This study shows that NF - kB might coordinate a network of immune - suppressor genes whose products enable tumor cells to evade adaptive immunity,» he adds.

Although changes in treatment methodology still have to be studied, Dr. Cripe believes it may be that the timing of various treatments is what matters, and that perhaps initially suppressing immunity could allow the virus to infect a large number of tumor cells before relieving the immunosuppression to allow the body's own T cells to fight off the tumor.

The vaccine harnesses the natural process of T - cell immunity to tumors, but enhances it to help overcome tumors» formidable defenses.

Different classes of MHC molecules exist and are involved in immunity against pathogens and tumor cells as well as the formation of immune tolerance to self - antigens.

Scientists hope to target these sites of tumor growth with therapies that can control abdominal tumors and assist anti-tumor immunity.

«Recent successes in cancer immunotherapy — in the form of immune checkpoint inhibitors and adoptive T cell transfer — demonstrate how activated immune cells can eradicate tumors, but until now we didn't fully appreciate immunosurveillance or the role of adaptive immunity in tumor formation,» said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego School of Medicine.

«Our findings indicate the existence of long - distance interactions between lung tumors and bones: lung tumors remotely activate osteoblasts, and those bone cells, in turn, shape immunity by supplying tumors with cancer - promoting neutrophils,» says Pittet, who is an associate professor of Radiology at Harvard Medical School.

In a previous study, investigators at the Cancer Institute showed that using a vaccine treatment for bladder and breast cancer tumors in laboratory models resulted in a reversal of the traditional immune blockade, as well as the development of tumor specific immunity throughout the body.

Gain an understanding of how therapeutic interventions targeting dendritic cells can promote tumor immunity and enhance the efficacy of cancer therapy

Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack against those tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many tumor types.

This made them suspect that by sharing exposure to various types of bacteria, the TAC mice had acquired microbes from JAX mice that somehow enhanced their immunity to tumors.

[i] Furthermore, [we] demonstrated that an MHC like molecule, called CD1d, loaded with a glycolipid ligand, called alphaGalCer, also targeted to the tumor cells by monoclonal antibodies, was capable to specifically inhibit tumor growth in vivo and to give a sustained activation of the Natural Killer Cells known to be important in the innate immunity.

According to Faron, the Clevegen antibody is well differentiated from competing products by its ability to specifically target TAMs of the M2 variety (which facilitate tumor growth) while sparing M1 macrophages that support antitumor immune activation and desirable immunity in general.

2016 - present Internist in charge, Clinic of Myositis, Unit of Clinical Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano 2013 - present Associate Professor of Internal Medicine, Università Vita - Salute San Raffaele, Milano 2013 - present Clinical Coordinator, Autoimmunity and Gender Medicine, IRCCS Ospedale San Raffaele, Milano 2009 - present Group leader, Innate Immunity and Tissue Remodeling Unit, IRCCS Ospedale San Raffaele, Milano 2002 - present Internist in charge, High Risk Pregnancy Unit, Department of Obstetrics and Gynecology, IRCCS Ospedale San Raffaele, Milano 2003 - 2013 Physician Scientist, Division of Internal Medicine, IRCCS Ospedale San Raffaele, Milano 1999 - 2002 Intern, Division of Internal Medicine, IRCCS Ospedale San Raffaele Milano 1997 - 1999 PhD student, Laboratory of Tumor Immunology, IRCCS Ospedale San Raffaele, Milano 1995 - 1997 Postdoc, Center d'Immunologie INSERM - CNRS de Marseille - Luminy, Marseille, France 1994 - 1995 Fellow, Laboratory of Tumor Immunology, IRCCS Ospedale San Raffaele, Milano

Direct Tumor Vaccination Shown to Induce Anti-Tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer MedicalNewsToday.com - March 27, 2017

Research Focus: My main interest is to study the role of Tumor Necrosis Super Family (TNFSF) members in mucosal immunity.

With respect to biological applications, the group is focusing on how cellular heterogeneity and cell - to - cell communication drive ensemble - level decision - making in the immune system, with an emphasis on «two - body» interaction (e.g., host cell - virus interactions, innate immune control of adaptive immunity, tumor infiltration by immune cells).

Although this benefit has not been seen in all patients treated with immunotherapy, one of the goals of the CCIR is to improve our understanding of the immune system, especially in the context of the tumor immune microenvironment, in order to modulate immunity to optimally enhance patient outcome.

Pramod K. Srivastava demonstrates the role of heat - shock proteins in tumor immunity and forms the company Antigenics (now Agenus) to explore their potential in cancer vaccines.

James P. Allison and Matthew Krummel demonstrate that a monoclonal antibody directed against the CTLA - 4 molecule in a mouse model of melanoma could result in the rejection of tumors and that this rejection also resulted in immunity to a second exposure to tumor cells.

Drew Pardoll, Glenn Dranoff, Elizabeth Jaffee, Hyam Levitsky, and colleagues conduct preclinical studies showing that a vaccine composed of tumor cells irradiated and genetically modified to produce immune system growth factor GM - CSF (granulocyte - macrophage colony - stimulating factor)-- which would become known as the therapeutic cancer vaccine GVAX — could induce potent, specific, and long - lasting anti-tumor immunity in multiple mouse tumor models.

For 2018, the CIMT program committee is preparing plenary sessions from pre-clinical research to clinical development on the topics of therapeutic vaccination, cellular therapy, improving immunity, tumor microenvironment, antibodies, regulatory research and immunoguiding.

It is known that macrophages are an important component of the innate immunity against tumors and they are attracted by locally secreted chemokines [4].

Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

iTeos focuses upon selected key suppressive mechanisms of immunity in cancer based on gene expression, association with immune cell subsets, protein expression in human tumors and biological validation.

CRI will present the 2016 William B. Coley Award for Distinguished Research in Tumor Immunology to Ton N. Schumacher, Ph.D., for his contributions to our understanding of how immune cells identify and target tumor - specific neoantigens, and how this capability can provide anti-tumor immuTumor Immunology to Ton N. Schumacher, Ph.D., for his contributions to our understanding of how immune cells identify and target tumor - specific neoantigens, and how this capability can provide anti-tumor immutumor - specific neoantigens, and how this capability can provide anti-tumor immutumor immunity.

The range of subjects includes, but is not limited to, immune cell development and senescence, signal transduction, gene regulation, innate and adaptive immunity, autoimmunity, infectious disease, allergy and asthma, transplantation, and tumor immunology.

The lab also found that apoptotic tumor cells serve as potent instigators of the T cell immune response and has worked on developing cancer vaccines to mimic PND tumor immunity.

Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.

Our goals include elucidating fundamental events and biologic endpoints surrounding RNase L that impact on viral replication cycles and tumor biology.Another area of research concerns the roles of innate immunity and genetics in prostate cancer.

Reference: Nature, «Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy,» published online Oct. 26, 2015

For example, new data has shown that tumors that are infiltrated by T cells — a type of white blood cell that plays an important role in immunity — translate to better outcomes in response to immunotherapy.

Interleukin 15 (IL - 15) regulates the development, survival, and functions of multiple innate and adaptive immune cells and plays a dual role in promoting both tumor cell growth and antitumor immunity.

Dr. Gollnick's laboratory explores how tumor cells co-opt the host immune system to promote chronic inflammation that leads to increased vascularization, suppression of anti-tumor immunity and increased tumor cell proliferation and migration.

Continuing research suggests that astragalus boosts immunity, acts as an anti-inflammatory, aids in the proper regulation of insulation and related illnesses, can slow tumor growth and protects the cardiovascular system.

Strong gut flora increases immunity, stops yeast production (goodbye, candida), blocks the harmful effects of radiation, and produces healthy enzymes that in one study showed to potentially block cancerous tumor growth and aid in chemotherapy effectiveness.

The numerous flavonoids found in astragalus appear to enhance cell - mediated immunity by increasing the number of T - helper cell type 2 cytokines, increasing levels of tumor necrosis factor and interleukin - 6, which stimulates the activity of macrophages, responsible for killing potentially harmful cells.

It is a powerful probiotic bacteria that improves immunity, combats tumor growth, and aids in digestion as evidenced by years of scientific research.